EGFR and lung carcinoma: However, existing EGFR-inhibitory drugs used to treat head and neck squamous cell carcinoma, lung cancer, and colorectal cancer have a limited response rate in TNBC 23, 24, and the role of EGFR in CTC clusters and polyclonal metastasis has yet to be studied.